Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?

Updates Surg. 2020 Jun;72(2):321-324. doi: 10.1007/s13304-020-00798-3.

Authors

Roberto Salvia¹, Giuseppe Malleo², Laura Maggino², Michele Milella³, Claudio Bassi²

Affiliations

¹ Unit of General and Pancreatic Surgery, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona Hospital Trust, P.Le L.A, Scuro 10, 37134, Verona, Italy. Roberto.salvia@univr.it.
² Unit of General and Pancreatic Surgery, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona Hospital Trust, P.Le L.A, Scuro 10, 37134, Verona, Italy.
³ Department of Medicine, Section of Medical Oncology, University of Verona Hospital Trust, Verona, Italy.

PMID: 32445032
DOI: 10.1007/s13304-020-00798-3

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Pancreatic Ductal / drug therapy*
Carcinoma, Pancreatic Ductal / surgery*
Fluorouracil / administration & dosage
Humans
Irinotecan / administration & dosage
Leucovorin / administration & dosage
Neoadjuvant Therapy / methods*
Neoadjuvant Therapy / trends*
Oxaliplatin / administration & dosage
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / surgery*

Substances

folfirinox
Oxaliplatin
Irinotecan
Leucovorin
Fluorouracil